Analysts’ Top Healthcare Picks: Edgewise Therapeutics (EWTX), Sarepta Therapeutics (SRPT)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Edgewise Therapeutics (EWTX – Research Report) and Sarepta Therapeutics (SRPT – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Edgewise Therapeutics (EWTX)
Wedbush analyst David Nierengarten maintained a Buy rating on Edgewise Therapeutics today and set a price target of $32.00. The company’s shares closed last Friday at $29.59.
According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Edgewise Therapeutics with a $39.33 average price target, implying a 30.7% upside from current levels. In a report issued on March 11, H.C. Wainwright also maintained a Buy rating on the stock with a $42.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Sarepta Therapeutics (SRPT)
In a report released today, Yun Zhong from Wedbush maintained a Buy rating on Sarepta Therapeutics, with a price target of $29.00. The company’s shares closed last Friday at $16.40.
According to TipRanks.com, Zhong is ranked 0 out of 5 stars with an average return of
Sarepta Therapeutics has an analyst consensus of Hold, with a price target consensus of $21.29, representing a 21.9% upside. In a report issued on March 12, Mizuho Securities also reiterated a Buy rating on the stock with a $31.00 price target.
